Chemoimmunotherapy, known as the combination of chemotherapy and IC inhibitors such as atezolizumab (anti-PDL1) or pembrolizumab (anti-PD1), is an advance in first-line cancer therapy, including for TNBC patients [43, 68]. This evidence concerns the gene PDCD1 and cancer.